Just as it looked like Bristol Myers Squibb might never catch up with its rivals in frontline lung cancer treatment, the company has achieved success in a new combination.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
